Introduction {#sec1-1}
============

*Portulaca oleracea* L. is distributed in the temperate and tropical regions of the world, which has not only high nutritional value but also resistive effect of inflammatory,\[[@ref1]\] neuroprotective,\[[@ref2]\] antitumor,\[[@ref3]\] and antioxidation.\[[@ref4]\] This is mainly due to the fact that it contains many bioactive substances such as alkaloids\[[@ref5][@ref6][@ref7][@ref8]\] and flavonoids,\[[@ref9]\] in which the alkaloids presented remarkable anti-inflammatory.\[[@ref10][@ref11][@ref12]\]

In the study, the 7\'-ethoxy-*trans* -feruloyltyramine (ETFT) \[[Figure 1](#F1){ref-type="fig"}\] was obtained from purslane for the first time. Its structure was identified by comparing with literature.\[[@ref13]\] The related spectrums are shown in Supplementary Figures 7-15, and its detailed ^1^H and ^13^C NMR data is shown in [Supplementary Table 1](#T1){ref-type="table"}.

![Structure of 7\'-ethoxy-*trans*-feruloyltyramine](IJPharm-52-130-g001){#F1}

###### 

^1^H NMR (500 MHz) and ^13^C NMR (125 MHz) data of 7'-ethoxy-*trans*-feruloyltyramine in MeOD

  Position   *δ*~C~   Type    *δ*~H~ (*J* in Hz)
  ---------- -------- ------- ------------------------------
  1          128.32   C       
  2          111.58   CH      7.13 (1H, d, 1.85)
  3          149.33   C       
  4          149.91   C       
  5          116.49   CH      6.79 (1H, m)
  6          123.32   CH      7.03 (1H, dd, 1.90; 8.25)
  7          142.21   CH      7.44 (1H, d, 15.7)
  8          118.71   CH      6.47 (1H, d, 15.75)
  9          169.24   C       
  3-OCH~3~   56.42    CH~3~   3.88 (3H, s)
  1´         132.20   C       
  2´/6´      129.08   CH      7.18 (1H, m)
  3´/5´      116.29   CH      6.79 (1H, m)
  4´         158.41   C       
  7´         81.35    CH      4.37 (1H, q, 6.48)
  8´         47.20    CH~2~   H~a~=3.40; H~b~=3.49 (2H, m)
  1´´        65.13    CH~2~   3.37 (2H, m)
  2´´        15.57    CH~3~   1.16 (3H, t, 7.05)

The antioxidation and anticholinesterase effects of ETFT were studied; in addition, the metabolism of ETFT in the rat\'s plasma, urine, as well as feces after intravenously administrated was also investigated by the ultra-high-performance liquid chromatography electrospray coupled with quadrupole time-of-flight mass spectrometry.

Experimental Method {#sec1-2}
===================

Antioxidation assay {#sec2-1}
-------------------

Different concentrations (0.25, 0.20, 0.15, 0.10, and 0.05 mg/mL) of ETFT and the 50 μg/mL 1,1-diphenyl-2-picrylhydrazyl (DPPH) solution were prepared. Vitamin C and butylated hydroxyl anisole were used as positive controls, and the methanol was used as the blank control. The absorbance was detected by a U-3010 spectrophotometer at 517 nm.

Anticholinesterase assay {#sec2-2}
------------------------

The concentrations of ETFT (0.30, 0.25, 0.20, 0.15, and 0.10 mg/mL) and 0.2 U/mL AChE, 15 mmol/L ATCI, and 15 mmol/L DTNB were prepared. For the positive control group, eserine was selected, and for the blank group, methanol was applied. The absorbance was detected at 405 nm using a 96-well microplate reader (HBS-1096A).

Instrumentation and condition {#sec2-3}
-----------------------------

Agilent 1290 UHPLC (Agilent, Waldbronn, Germany) with ODS column (3.0 mm × 150 mm, particle size, 1.8 μm) was applied with the mobile phase of 0.1% formic acid (A) and acetonitrile (B). The program system was 15%--70% (B) at 0--10 min, with 0.3 mL/min, and the oven temperature was at 60°C. An Agilent 6520 Q-TOF/MS (Agilent, Waldbronn, Germany) was coupled to the UHPLC system through an ESI interface. The MS parameters in the positive mode: drying gas (nitrogen);10 L/min at 330°C; nebulizer pressure (45 psi); fragmentation voltage 150 V; ESI Vcap of 3500 V; and collision energy (30 eV). Full-scan information acquisition in the positive ionization mode was m/z 100--800.

Animal experiments {#sec2-4}
------------------

Male Sprague--Dawley rats (200 ± 20 g) were used for the animal assay, and this experiment was approved by the Committee of Ethics of Animal Experimentation of Liaoning University of Traditional Chinese Medicine with the approval number 2019YS(DW)-009-01.

After intravenous administration of ETFT (4 mg/kg), 300 μL blood sample was gathered from the orbital venous at 3, 10, and 30 min. Meanwhile, the urine as well as feces samples were respectively collected within 0--24 h.

Sample preparation {#sec2-5}
------------------

100 μL sample and 500 μL methanol were added into EP tubes, vortex mixing for 60 s, centrifuging for 15 min (3000 rpm) to remove the protein. The residue was reconstituted in a 100 μL initial mobile phase, and then centrifugating it for 3 min (10,000 rpm). Finally, a 5 μL aliquot was injected for determination.

Results {#sec1-3}
=======

Antioxidation assay {#sec2-6}
-------------------

DPPH scavenging rate of ETFT is shown in Supplementary Figure 1, indicating that the oxidation effect increased along with the increase of concentration, with IC~50~ to be 0.058 mg/mL.

Anticholinesterase assay {#sec2-7}
------------------------

The result of the anticholinesterase assay is shown in Supplementary Figure 2, suggesting that the ETFT exerted a dose-dependent inhibitory effect against the AChE with IC~50~ values of 0.106 mg/mL.

Metabolism study {#sec2-8}
----------------

### Analysis of plasma, urine, and feces samples {#sec3-1}

The chromatograms of the plasma, urine, and feces samples in positive ion mode are shown in Supplementary Figures 3 and 4. All of the fragment ions are shown in Supplementary Figures 5 and 6. The MS data of nine metabolic products are listed in [Supplementary Table 2](#T2){ref-type="table"}.

###### 

Ultra-high-performance liquid chromatography electrospray coupled with quadrupole time-of-flight mass spectrometry data of nine metabolites of 7'-ethoxy-*trans*-feruloyltyramine in rats

  No.   Retention time (min)   Experimental (m/z)   Theoretical (m/z)   Formula             Metabolic process                              Specimen
  ----- ---------------------- -------------------- ------------------- ------------------- ---------------------------------------------- ----------
  M-1   4.4                    199.1240             199.1189            C~8~H~6~O~4~S       Oxidation, reduction, dehydration, sulfation   Plasma
  M-2   5.0                    309.1808             309.1301            C~15~H~16~O~7~      Hydrolysis, glucuronidation                    Plasma
  M-3   5.2                    367.1857             367.1769            C~18~H~22~O~8~      Glucuronidation, dehydration, decarbonation    Plasma
  M-4   6.5                    337.1750             337.1750            C~9~H~5~O~10~S~2~   Oxidation, sulfation                           Plasma
  M-5   9.4                    346.3313             346.1933            C~19~H~23~NO~5~     Oxidation                                      Plasma
  M-6   9.4                    346.3313             346.1611            C~18~H~19~NO~6~     Oxidation                                      Plasma
  M-7   7.4                    271.0609             271.2046            C~12~H~16~NO~4~S    Glutathionylation                              Urine
  M-8   7.8                    188.0708             188.1268            C~7~H~7~O~4~S       Sulfation                                      Urine
  M-9   9.7                    348.2179             348.1769            C~18~H~21~NO~6~     Reduction                                      Urine

### Identification of the metabolites {#sec3-2}

All metabolites and the metabolic pathway are shown in [Figure 2](#F2){ref-type="fig"}.

![Proposed major metabolic pathways of 7\'-ethoxy-*trans*-feruloyltyramine](IJPharm-52-130-g002){#F2}

Oxidation

M-5 (m/z 346.3313) was in the same value with M-6. M-5 was from ETFT\'s olefine reduced and methoxy oxidization. M-6 was from ETFT in which both N and ethoxyl were oxidized to hydroxyl.

Glucuronide conjugates

M-2 (m/z 309.1808) was formed by ferulic acid, the hydrolysate of M-6, via the serial process of glucuronidation (370.1362 Da) and losing a H~2~O and a CO~2~. M-3 (m/z 367.1857) was formed from the fragmentation ion (138.0778), which experienced glucuronidation (491.2049 Da) and then losing two H~2~O and two CO~2~.

Sulfate conjugates

M-1 (m/z 199.1240) was formed by -SO~3~ (80.0642 Da) combining with the fragmentation ion (120.0626 Da) that was obtained when M-5 happened oxidation and reduction reaction, then losing H~2~O. M-4 (m/z 337.1750) was formed by two -SO~3~ (80.0642 Da) combining with the fragmentation ion (176.0523 Da) of M-6. M-8 (m/z 188.1268) was the combination of -SO~3~ (80.0642 Da) and the fragmentation ion (107.0547 Da).

Glutathione conjugates

M-7 (m/z 271.0609) was the combination of C~9~H~11~O~2~ (151.0857) and + C~3~H~5~NO~2~S (119.111 Da).

Reduction

M-9, the fragment ion at m/z 348.2179, was the reduction of M-6 in olefins.

Discussion {#sec1-4}
==========

The bioactive assays indicated that the ETFT has a remarkably antioxidation effect compared with that of BHA, although its antioxidation effect has no more than that of Vitamin C. Moreover, it also exhibited an anticholinesterase effect with dose-dependent.

In the metabolism experiment, no ETFT was detected after intravenous administration, but a peak consisting of two molecules (M-5 and M-6) was found at 3 min and gradually enhanced at 10 and 30 min, which means that ETFT has converted into M-5 and M-6. And furthermore, other metabolites were formed from M-5 and M-6. Among nine metabolites, six metabolites (M-1 to M-6) were found in the plasma, and three metabolites (M-7 to M-9) were found in the urine samples. Any metabolites were not found in the feces, suggesting that ETFT was not metabolized via bile.
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###### 

Antioxidation effect of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

Anticholinesterase effect of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

The extracted ion chromatograms of metabolites from 7\'-ethoxy-*trans*-feruloyltyramine in the rat plasma. (a) Blank rat plasma; rat plasma collected at (b) 3 min, (c) 10 min, and (d) 30 min after intravenous administration

###### 

The extracted ion chromatograms of metabolites from 7\'-ethoxy-*trans*-feruloyltyramine in the rat urine and feces. (a) blank rat urine; (b) rat urine after intravenous administration of 7\'-ethoxy-*trans*-feruloyltyramine; (c) blank rat feces; (d) rat feces collected after intravenous administration of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

MS/MS spectra of M-5 and M-6 in rat plasma collected at 3, 10, and 30 min after intravenous administration of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

MS/MS spectra that phase I and phase II metabolism in rat urine and plasma collected at 30 min after intravenous administration of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

Ultraviolet spectrum of 7\'-ethoxy-*trans*-feruloyltyramine in methanol

###### 

Infrared spectrum of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

^1^H NMR (500 MHz) spectrum of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

^13^C NMR (125 MHz) spectrum of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

DEPT spectrum of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

^1^H-^1^H COSY spectrum of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

HMBC spectrum of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

HSQC spectrum of 7\'-ethoxy-*trans*-feruloyltyramine

###### 

NOESY spectrum of 7\'-ethoxy-*trans*-feruloyltyramin
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